Skip to content

Type: White Papers

Accelerating Investigation of New Therapies in Earlier Metastatic Treatment Settings

Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Clinical Trials

Supporting a Patient-Centric Approach to Dose Optimization in Oncology: The Essential Role of Patient-Reported Outcomes (PROs)

Beyond Breakthrough: Optimizing the Breakthrough Therapy Designation

Multi-Cancer Early Detection Screening Tests: Considerations for Use of Real-World Data

Assessing the Use of ctDNA as an Early Endpoint in Early-Stage Disease

Optimizing Dosing in Oncology Drug Development

Expedited Development of Diagnostics for Therapies Targeting Rare Biomarkers or Indications

Harmonizing the Definition and Reported of Cytokine Release Syndrome (CRS) in Immuno-Oncology Clinical Trials

2018 Annual Meeting Panel 2: Exploring the Use of Circulating Tumor DNA as a Monitoring Tool for Drug Development